• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by MBX Biosciences Inc.

    5/12/25 10:44:44 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MBX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    MBX Biosciences, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    55287L101

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    55287L101


    1Names of Reporting Persons

    Wellington Management Group LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,525,931.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,638,521.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,638,521.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.9 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    55287L101


    1Names of Reporting Persons

    Wellington Group Holdings LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,525,931.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,638,521.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,638,521.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.9 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    55287L101


    1Names of Reporting Persons

    Wellington Investment Advisors Holdings LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,525,931.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,638,521.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,638,521.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.9 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    55287L101


    1Names of Reporting Persons

    Wellington Management Company LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,525,931.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,618,783.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,638,521.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.8 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    MBX Biosciences, Inc.
    (b)Address of issuer's principal executive offices:

    11711 North Meridian Street, Suite 300, Carmel IN 46032
    Item 2. 
    (a)Name of person filing:

    Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP Wellington Management Company LLP
    (b)Address or principal business office or, if none, residence:

    c/o Wellington Management Company LLP, 280 Congress Street, Boston MA 02210
    (c)Citizenship:

    Wellington Management Group LLP - Massachusetts Wellington Group Holdings LLP - Delaware Wellington Investment Advisors Holdings LLP - Delaware Wellington Management Company LLP - Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    55287L101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See the responses to Item 9 on the attached cover pages.
    (b)Percent of class:

    7.89  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    See the responses to Item 6 on the attached cover pages.

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    See the responses to Item 8 on the attached cover pages.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows: Wellington Biomedical Innovation Master Investors (Cayman) II L.P. Wellington Biomedical Innovation Master Investors (Cayman) II, L.P.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Wellington Group Holdings LLP - HC Wellington Investment Advisors LLP - HC Wellington Management Global Holdings, Ltd. - HC One or more of the following investment advisers (the "Wellington Investment Advisers"): Wellington Management Company LLP - IA Wellington Management Canada LLC - IA Wellington Management Singapore Pte Ltd - IA Wellington Management Hong Kong Ltd - IA Wellington Management International Ltd - IA Wellington Management Japan Pte Ltd - IA Wellington Management Australia Pty Ltd - IA The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Wellington Management Group LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:05/12/2025
     
    Wellington Group Holdings LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:05/12/2025
     
    Wellington Investment Advisors Holdings LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:05/12/2025
     
    Wellington Management Company LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:05/12/2025
    Get the next $MBX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MBX

    DatePrice TargetRatingAnalyst
    4/10/2025$38.00Mkt Outperform
    Citizens JMP
    10/8/2024$44.00Buy
    Guggenheim
    10/8/2024$40.00Buy
    Stifel
    10/8/2024$35.00Buy
    Jefferies
    10/8/2024$30.00Overweight
    JP Morgan
    More analyst ratings

    $MBX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in cash, cash equivalents and marketable securities as of March 31, 2025; expected to support operations into mid-2027 CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent corporate

      5/12/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

      CARMEL, Ind., April 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the Citizens Life Sciences Conference on May 7 and the RBC 2025 Global Healthcare Conference on May 21. The Citizens Life Sciences Conference Date: Wednesday, May 7, 2025Format: Fireside chat and 1x1 meetingsTime: 3:00 p.m. – 3:25 p.m. ETLocation: New York, NY The RBC 2025 Global Healthcare Conference Date: Wednesday, Ma

      4/22/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors

      CARMEL, Ind., April 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Steve Hoerter as an independent director to the Company's Board of Directors. Mr. Hoerter brings over three decades of pharmaceutical commercialization and executive leadership experience as well as a proven track record of building and growing life science companies. "I am thrilled to welcome Steve Hoerter to the Company's Board as an independent director," said Kent Hawryluk, President and Chief

      4/7/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    Leadership Updates

    Live Leadership Updates

    See more
    • MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in cash, cash equivalents and marketable securities as of March 31, 2025; expected to support operations into mid-2027 CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent corporate

      5/12/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors

      CARMEL, Ind., April 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Steve Hoerter as an independent director to the Company's Board of Directors. Mr. Hoerter brings over three decades of pharmaceutical commercialization and executive leadership experience as well as a proven track record of building and growing life science companies. "I am thrilled to welcome Steve Hoerter to the Company's Board as an independent director," said Kent Hawryluk, President and Chief

      4/7/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MBX Biosciences Announces Additions to Leadership Team

      Chatan Charan, Ph.D. appointed as Senior Vice President, Pharmaceutical Development and CMC Mark Hope appointed as Senior Vice President, Regulatory and Quality CARMEL, Ind., March 05, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointments of Chatan Charan, Ph.D. as Senior Vice President, Pharmaceutical Development and Chemistry, Manufacturing and Controls (CMC) and Mark Hope as Senior Vice President, Regulatory and Quality. "We are excited to welcome Chatan and Mark, who wi

      3/5/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Pescovitz Ora H. bought $45,312 worth of shares (7,693 units at $5.89), increasing direct ownership by 46% to 24,329 units (SEC Form 4)

      4 - MBX Biosciences, Inc. (0001776111) (Issuer)

      4/10/25 8:39:55 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Gordon Carl L bought $2,020,756 worth of shares (190,672 units at $10.60) (SEC Form 4)

      4 - MBX Biosciences, Inc. (0001776111) (Issuer)

      2/19/25 5:56:33 PM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Orbimed Advisors Llc bought $2,020,756 worth of shares (190,672 units at $10.60) (SEC Form 4)

      4 - MBX Biosciences, Inc. (0001776111) (Issuer)

      2/19/25 5:52:03 PM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by MBX Biosciences Inc.

      SCHEDULE 13G/A - MBX Biosciences, Inc. (0001776111) (Subject)

      5/12/25 10:44:44 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by MBX Biosciences Inc.

      10-Q - MBX Biosciences, Inc. (0001776111) (Filer)

      5/12/25 8:19:03 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MBX Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MBX Biosciences, Inc. (0001776111) (Filer)

      5/12/25 8:11:46 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Pescovitz Ora H. bought $45,312 worth of shares (7,693 units at $5.89), increasing direct ownership by 46% to 24,329 units (SEC Form 4)

      4 - MBX Biosciences, Inc. (0001776111) (Issuer)

      4/10/25 8:39:55 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hoerter Steven L.

      4 - MBX Biosciences, Inc. (0001776111) (Issuer)

      4/9/25 8:27:25 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Hoerter Steven L.

      3 - MBX Biosciences, Inc. (0001776111) (Issuer)

      4/7/25 8:24:23 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by MBX Biosciences Inc.

      SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)

      11/8/24 10:52:39 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by MBX Biosciences Inc.

      SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)

      11/1/24 5:38:56 PM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by MBX Biosciences Inc.

      SC 13D - MBX Biosciences, Inc. (0001776111) (Subject)

      9/23/24 6:07:21 PM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citizens JMP initiated coverage on MBX Biosciences with a new price target

      Citizens JMP initiated coverage of MBX Biosciences with a rating of Mkt Outperform and set a new price target of $38.00

      4/10/25 12:42:19 PM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on MBX Biosciences with a new price target

      Guggenheim initiated coverage of MBX Biosciences with a rating of Buy and set a new price target of $44.00

      10/8/24 7:30:45 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on MBX Biosciences with a new price target

      Stifel initiated coverage of MBX Biosciences with a rating of Buy and set a new price target of $40.00

      10/8/24 7:30:45 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    Financials

    Live finance-specific insights

    See more
    • MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

      Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin in 2H 2025 Phase 1 trial in healthy volunteers showed MBX 1416 was generally well-tolerated with a favorable safety profile Pharmacokinetic results demonstrated sustained dose-dependent exposure and support once-weekly dosing Company to host conference call to discuss results today at 8:30 am ET CARMEL, Ind., Jan. 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today annou

      1/7/25 7:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care